title: Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
abstract: We have developed a web-based user-interface (web interface) to enhance the usefulness of health-economic evaluations to support decision making (http://pcv.healtheconomics.nl). It allows the user to interact with a health-economic model to evaluate predefined and customized scenarios and perform sensitivity analysis. To explore its usefulness, it was applied to an evaluation of cost-effectiveness of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine (PCV7), that was used to support a policy decision on the inclusion of PCV7 in the national vaccination program (NVP) of the Netherlands. We used a decision-tree analytic model to project the impact of infant vaccination with four doses of PCV7 on an annual cohort of infants born in the Netherlands. The base-case analysis includes the beneficial effects on unvaccinated individuals (herd protection). Additional scenarios varying the number of doses, discount rate for effects and the number of serotypes in the vaccine were evaluated and can be analysed on the web. Our model projects a base-case incremental cost-effectiveness ratio (iCER) of euro14,000 (95% uncertainty interval (UI): 9,800-20,200) per quality adjusted life year (QALY) or euro15,600 (95% UI: 11,100-23,900) per life year gained (LYG).
authors.affiliation: Social Pharmacy, Pharmacoepidemiology & Pharmacotherapy, University of Groningen, and Base-Case, Healthcare Decision Support, Groningen, The Netherlands. g.hubben@rug.nl
authors.forename: G A A
authors.initials: GA
authors.lastname: Hubben
authors.forename: J M
authors.initials: JM
authors.lastname: Bos
authors.forename: D M
authors.initials: DM
authors.lastname: Glynn
authors.forename: A
authors.initials: A
authors.lastname: van der Ende
authors.forename: L
authors.initials: L
authors.lastname: van Alphen
authors.forename: M J
authors.initials: MJ
authors.lastname: Postma
mesh_terms: D016470:Bacteremia / Q000453:epidemiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D006291:Health Policy; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D032521:Immunity, Herd; D017589:Immunization Programs / Q000191:economics / Q000592:standards*; D007223:Infant; D020407:Internet; D008586:Meningitis, Pneumococcal / Q000453:epidemiology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000008:administration & dosage*; D018803:Models, Economic; D009426:Netherlands / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011018:Pneumonia, Pneumococcal / Q000453:epidemiology / Q000517:prevention & control; D014611:Vaccination / Q000191:economics
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines